SCHEMBL7770043

SCHEMBL7770043

NC(=O)OCCCI

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8813924 0.92
SCHEMBL28689983 0.91 LMNA (0.40)
SCHEMBL22326320 0.90 LMNA (0.42)
SCHEMBL22326280 0.90 LMNA (0.42)
SCHEMBL5357389 0.90 LMNA (0.42)
SCHEMBL113903 0.83
SCHEMBL2746597 0.83 TSHR (0.52)
SCHEMBL2745809 0.83 LMNA (0.52)
SCHEMBL7297898 0.81
SCHEMBL5721317 0.80 TSHR (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118440006-A N-containing material2-Acyl-2-amino imidazole ring compound, preparation method and application thereof 烟台新药创制山东省实验室 2024-08-06 CN disclosed
CN-116987045-A Heteroatom-containing substituted benzoxazinone derivative and preparation method and application thereof 中国医学科学院药物研究所 2023-11-03 CN disclosed
CN-116997449-A Enhanced wood preservative containing zinc and boron 阿萨达有限责任公司 2023-11-03 CN disclosed
CN-108778273-B Bicyclic aryl monocyclic beta-lactam compounds and methods of use thereof for treating bacterial infections 默沙东公司 2022-06-17 CN disclosed
CN-112996518-A WD40 repeat domain protein 5(WDR5) degradation/disruption compounds and methods of use 西奈山伊坎医学院 2021-06-18 CN disclosed
EP-3122346-B1 TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF MERCK SHARP & DOHME (US) 2020-07-15 EP disclosed
CN-108368040-A Diaryl monocyclic β -lactam compounds and methods of use thereof for treating bacterial infections 默沙东公司 2018-08-03 CN disclosed
US-9815846-B2 TrkA kinase inhibitors, compositions and methods thereof MERCK SHARP & DOHME CORP. (US) 2017-11-14 US disclosed
US-20170114071-A1 TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF MERCK SHARP & DOHME CORP. (US) 2017-04-27 US disclosed
EP-3122346-A2 TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF Merck Sharp & Dohme Corp. (US) 2017-02-01 EP disclosed
CN-103079553-B Be used for the treatment of the N-acyl amino acid derivative of the skin disorder of such as liparitosis HELIX BIOMEDIX INC. (US) 2016-01-20 CN disclosed
WO-2015148344-A2 TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF MERCK SHARP & DOHME CORP. (US) 2015-10-01 WO disclosed
CN-103079553-A N-acyl amino acid derivatives for treating skin conditions such as cellulite HELIX BIOMEDIX INC 2013-05-01 CN disclosed
EP-0765879-B1 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests SANKYO CO (JP) 2001-02-14 EP disclosed
US-5861429-A MITICIDES AND ANTHELMINTICS SANKYO COMPANY, LIMITED (JP) 1999-01-19 US disclosed
US-5691319-A ANTICARCINOGENIC AGENTS SANKYO COMPANY, LIMITED (JP) 1997-11-25 US disclosed
EP-0765879-A1 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests SANKYO COMPANY LIMITED (JP) 1997-04-02 EP disclosed
EP-0536936-B1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use SANKYO CO (JP) 1996-08-14 EP disclosed
EP-0536936-A1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use Sankyo Company Limited (JP) 1993-04-14 EP disclosed